65-LB: Real-World Continuous Glucose Monitoring Data on Time-in-Range from a U.S. Population, 2015–2019

Aims: Improvements in technology and access have led to growing adoption of continuous glucose monitoring (CGM). Targets for glucose metrics including time in range (TIR) have been published. We aimed to investigate i) the proportion of people with ≥70% TIR and ii) the proportion with ≥70% TIR and Methods: Data were collected from 2015 to 2019 from the Cornerstone4Care (C4C) database, a freely available patient support program for people with both type 1 diabetes (T1D) and type 2 diabetes (T2D) on any treatment type. CGM traces were divided into 14-day periods according to the ambulatory glucose profile (AGP)-reporting system. Only profiles with data aligned with these standards were included. Patient data are presented using the first or the mean of all AGP profiles. Results: In total, 484 persons uploaded CGM-data to the database (4727 AGPs); 242 had T1D and 74 had T2D (self-reported), the rest were unknown (Table). People uploaded between 1 and 75 AGPs (mean=10). Average TIR (70-180 mg/dL) based on mean profiles was 63%, 68% and 64% for T1D, T2D and all, respectively. Conclusions: Less than half of the population achieved ≥70% TIR, ~30% with ≥70% TIR and Disclosure R. M. Bergenstal: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Consultant; Self; Abbott Diabetes, Ascensia, Dexcom, Inc., Eli Lilly and Company, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Other Relationship; Self; HealthPartners Institute, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, NIDDK, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare. E. Hachmann-nielsen: Employee; Self; Novo Nordisk A/S. J. Tarp: Employee; Self; Novo Nordisk. K. Kvist: Employee; Self; Novo Nordisk A/S. J. B. Buse: Consultant; Self; Cirius Therapeutics, CSL Behring, Fortress Biotch, Mellitus Health, Moderna, Pendulum Therapeutics, Praetego Inc., Stability Health, Zealand Pharma A/S, Other Relationship; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, vTv Therapeutics, Research Support; Self; NovaTarg Therapeutics, Novo Nordisk, Sanofi, Tolerion, Inc., vTv Therapeutics, Stock/Shareholder; Self; Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Stability Health. Funding Novo Nordisk A/S